In August 2020, Salubris received the Notice of Approval of Clinical Trials from National Medical Products Administration, and initiated human clinical trials.
Recently, Alain Medical (Beijing) Co., Ltd. (hereinafter referred to as "Alain Medical ") received the Medical Device Registration Certificate approved and issued by National Medical Products Administration, and the MAURORA ® Rapamycin drug-eluting v
Salubris Biotherapeutics, Inc., (hereinafter referred to as "SalubrisBio"), as a wholly owned subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd., submitted a clinical application for SAL007 to FDA on January 23, 2020, and was successfully appro
On December 25, 2019, Salubris formally signed an agreement with Japan's JAPAN TOBACCO INC. (hereinafter referred to as "JT") at its headquarters in Shenzhen
Recently, Genemen Biotech (Suzhou) Co., Ltd., a subsidiary of Shenzhen Salubris Pharmaceuticals Co., Ltd., received the Drug Registration Approval Document of "Recombinant Teriparatide for Injection" (Xinfutai) approved and issued by National Medical
Recently, Salubris's Pitavastatin Calcium Tablets 2mg (trademark: Xinliming) was approved for market launch. So far, Salubris have involved in lipid-lowering, antihypertensive and antithrombotic filed, further strengthening its dominant position in t
